Phosphatidic Acid-TRIM59-Olig2 Signaling Couples Metabolic Dysfunction to Myelination Failure in PWMI

Area of Science:

• Neuroscience
• Metabolomics
• Developmental Biology

Background:

• Cerebral palsy (CP) is a major neurodevelopmental disorder often caused by preterm white matter injury (PWMI).
• Oligodendrocyte precursor cell (OPC) differentiation failure is a key factor in PWMI, but the underlying metabolic mechanisms are not well understood.

Purpose of the Study:

• To identify metabolic signatures associated with CP in preterm infants.
• To elucidate the role of specific metabolites, particularly phosphatidic acid (PA), in PWMI and OPC dysfunction.

Main Methods:

• Untargeted lipidomic and metabolomic profiling of serum from preterm infants.
• Validation in PWMI mouse models and in vitro OPC models subjected to oxygen-glucose deprivation/reoxygenation (OGD/R).
• Mechanistic studies involving protein-protein interactions, ubiquitination assays, and inhibition of PA synthesis.

Main Results:

• A CP-associated metabolic signature was identified, with phosphatidic acid (PA) being consistently elevated and highly discriminative.
• Increased PA levels were observed in serum and brains of PWMI mice and in stressed OPCs, where PA impaired OPC differentiation and myelination.
• PA was found to stabilize TRIM59, leading to increased degradation of Olig2, a crucial transcription factor for OPC maturation. Inhibition of PA synthesis rescued these deficits.

Conclusions:

• Phosphatidic acid (PA) is identified as a potential metabolic risk factor for CP in preterm infants.
• A novel signaling axis (PA-TRIM59-Olig2) is uncovered, linking lipid metabolism to OPC differentiation failure in PWMI.
• Targeting PA synthesis presents a potential therapeutic strategy for mitigating PWMI and CP.